
    
      1.1 Primary Objective 1.1.1. To evaluate the maximum tolerated dose of nanoliposomal
      irinotecan with continuous low-dose temozolomide for patients with recurrent glioblastoma.

      1.1.2 To assess the preliminary response rate and progression free survival of nanaliposomal
      irinotecan with continuous low-dose temozolomide in patients with recurrent glioblastoma.

      1.2 Secondary Objectives 1.2.1 To evaluate the safety of nanoliposomal irinotecan with
      continuous low-dose temozolomide.
    
  